文献速递前列腺癌

基于血液标志物减少前列腺癌有组织检测中的MRI使用:OPT Stockholm3研究

Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study.
PubMed 文献 · Eur Urol Oncol · 2026-08-07

该研究在瑞典斯德哥尔摩-哥特兰地区开展实用性人群实施研究,评估将Stockholm3作为反射血检整合入前列腺癌有组织检测(OPT)的可行性、MRI使用减少及成本影响。2024年实验组PSA≥2 ng/ml者行Stockholm3,≥15%者行MRI;2023年对照组PSA≥3 ng/ml者行MRI。MRI使用减少64%,活检率及GG1、GG≥2癌检出均下降,但癌检出事件少、研究效能不足。

要点

  • Stockholm3反射血检可使OPT首轮MRI使用减少64%
  • PSA 2.0-2.9 ng/ml未检出癌症,但研究效能不足
  • Stockholm3单次92欧元可实现成本中性

核心结论

  • 将Stockholm3作为OPT首轮反射血检可行,并与MRI和活检数量减少相关。
  • PSA 2.0-2.9 ng/ml未检出癌症的发现应视为假设生成性。

研究设计与样本

  • 实验组(2024年)PSA≥2 ng/ml者行Stockholm3,Stockholm3≥15%者行MRI;对照组(2023年)按标准OPT,PSA≥3 ng/ml者行MRI。

主要发现

  • MRI使用从2023年2.7%(181/6663)降至2024年1.0%(70/7070),相对比例(RP)0.36(95%CI 0.28-0.48)。
  • 活检率从0.6%降至0.4%(RP 0.67;95%CI 0.41-1.07)。
  • GG1癌检出从0.17%(11/6663)降至0.08%(6/7070)(RP 0.51;95%CI 0.19-1.39)。
  • GG≥2癌检出从0.20%(13/6663)降至0.14%(10/7070)(RP 0.72;95%CI 0.32-1.65)。

关键数值与推荐

  • 实验组反射血检阈值:PSA≥2 ng/ml行Stockholm3,Stockholm3≥15%行MRI。
  • 对照组MRI阈值:PSA≥3 ng/ml。
  • Stockholm3单次92欧元可实现成本中性。
  • 将Stockholm3检测限于PSA≥3 ng/ml男性可减少MRI使用和成本。

临床怎么用

  • 在OPT项目中可考虑将Stockholm3作为反射血检整合,以减少MRI和活检使用。
  • 可考虑将Stockholm3检测限于PSA≥3 ng/ml男性以进一步降低MRI使用和成本。

局限性

  • 非随机设计。
  • 癌症事件数少。
  • 年龄范围受限(50-52岁)。
  • 随访时间短。
  • 研究效能不足以评估癌症检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We assessed the feasibility of implementation, reduction in magnetic resonance imaging (MRI) use, and cost implications of integrating Stockholm3 as a reflex blood test in organized prostate cancer testing (OPT). METHODS: This pragmatic, population-based implementation study included men aged 50-52 yr invited to OPT in 2023 (n = 17 801) and 2024 (n = 30 556) in Health Region Stockholm-Gotland. The experimental group (2024) had a Stockholm3 test if prostate-specific antigen (PSA) ≥2 ng/ml and an MRI if Stockholm3 ≥15%. The control group (2023) followed standard OPT (MRI if PSA ≥3 ng/ml). Outcomes were MRI use (primary), biopsies performed, detection of Grade Group (GG) 1 and GG ≥2 cancer, and Stockholm3 cost thresholds. Relative proportions (RPs) and decision-tree cost modeling were used. KEY FINDINGS AND LIMITATIONS: MRI use decreased by 64%, from 2.7% (181/6663) in 2023 to 1.0% (70/7070) in 2024 (RP 0.36; 95% confidence intervals [CI], 0.28-0.48); biopsy rates decreased from 0.6% to 0.4% (RP 0.67; 95% CI, 0.41-1.07). Detection of GG 1 cancer decreased from 0.17% (11/6663) to 0.08% (6/7070) (RP 0.51; 95% CI, 0.19-1.39), and detection of GG ≥2 cancer decreased from 0.20% (13/6663) to 0.14% (10/7070) (RP 0.72; 95% CI, 0.32-1.65). A cost of €92 per Stockholm3 test would achieve cost neutrality. Limiting Stockholm3 testing to men with PSA ≥3 ng/ml would reduce MRI use and costs. Study limitations include the nonrandomized design, few cancer events, restricted age range, and short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: Integrating Stockholm3 as a reflex test in the first round of an OPT program is feasible. Reflex testing at PSA ≥2 ng/ml and PSA ≥3 ng/ml was associated with reductions in the numbers of MRI scans and biopsies performed. No cancers were detected at PSA 2.0-2.9 ng/ml; however, the study was underpowered to assess cancer detection, and this finding should be considered hypothesis-generating.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Falagario UG, Hao S, Akre O, et al. Reducing MRI Use in Organized Prostate Cancer Testing Using Blood-based Biomarkers: The OPT Stockholm3 Study. Eur Urol Oncol. 2026. PMID: 42567734. doi:10.1016/j.euo.2026.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。